Corrigendum to “Structure–activity study for (bis)ureidopropyl- and (bis)thioureidopropyldiamine LSD1 inhibitors with 3-5-3 and 3-6-3 carbon backbone architectures” [Bioorg. Med. Chem. 23 (2015) 1601–1612]

Dual inhibitors of LSD1 and spermine oxidase

“…1), including oligoamines such as verlindamycin 1 (ref. [2][3][4][5] and related isosteric ureas and thioureas, 5,6 tranylcypromine-based irreversible inhibitors such as GSK2879552 (2) 7 and ORY-1001 (3), [8][9][10] reversible benzohydrazide inhibitors such as SP-2509 (4) 10 and triazole-based reversible inhibitors such as 5. 11 In addition, dithiocarbamate-urea hybrid LSD1 inactivators such as 6, 12 and linear [13][14][15][16] and cyclic 17,18 peptide inhibitors have been reported.…”

Bis‐thiourea Derivatives and Their Utility in Synthesis of Mono‐heterocyclic, Bis‐heterocyclic, and Fused Heterocyclic Systems

“…They have also demonstrated interesting pharmacological activities. They have been reported to display potent antitumor as well as antimalarial activities. Bis‐thioureas were extensively employed as organocatalysts in several asymmetric organic reaction providing high reactivity and enantioselectivity .…”

Inhibition of FAD-dependent lysine-specific demethylases by chiral polyamine analogues

“…23 Their bisurea and bisthiourea derivatives also inhibit LSD1 with an IC 50 value of approximately 5 mM for the most potent compound. 24 These inhibitors contained an alkyldiamine moiety. Also, long-chain polyamine analogues, which possess 10 secondary amino groups, inhibit LSD1.…”